AURA
Aura Biosciences, Inc.
1W: +10.3%
1M: +22.2%
3M: +12.0%
YTD: +23.6%
1Y: -12.6%
3Y: -35.7%
$6.55
-0.03 (-0.46%)
After Hours: $6.95 (+0.40, +6.03%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$5.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$415.9M
52W Range4.345-7.73
Volume344,687
Avg Volume218,313
Beta0.45
Dividend—
Analyst Ratings
Company Info
CEOElisabet de los Pinos
Employees106
SectorHealthcare
IndustryBiotechnology
IPO Date2021-10-29
Websiteaurabiosciences.com
85 Bolton Street
Boston, MA 02140
US
Boston, MA 02140
US
617 500 8864
About Aura Biosciences, Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Latest News
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update
12 Health Care Stocks Moving In Monday's Pre-Market Session
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Plavsic Mark | A-Award | 62,339 | — | 2026-03-02 |
| Plavsic Mark | A-Award | 112,661 | $6.14 | 2026-03-02 |
| Hopkins Janet Jill | A-Award | 89,056 | — | 2026-03-02 |
| Hopkins Janet Jill | A-Award | 160,944 | $6.14 | 2026-03-02 |
| Elazzouzi Amy | A-Award | 44,528 | — | 2026-03-02 |